Strong Memorial Hospital
- Type
- Teaching hospital
- Where
- Rochester, NY
- Medicare CCN
- 330285
- Received
- $22,760,402 in 1,509 records, 2024 ($1,874,911 general, $20,885,491 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
- Lobbying client: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 228 | $1,874,911 |
| 2024 | Research payment | 1,281 | $20,885,491 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,281 | $20,885,491 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 33 | $623,659 |
| Grant | 44 | $347,402 |
| Royalty or License | 6 | $247,278 |
| Consulting Fee | 7 | $230,128 |
| Long term medical supply or device loan | 39 | $190,392 |
| Space rental or facility fees (teaching hospital only) | 73 | $177,196 |
| Debt forgiveness | 10 | $43,861 |
| Education | 8 | $13,830 |
| Charitable Contribution | 8 | $1,162 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $1,226,893 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $246,042 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $226,095 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $183,851 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2024 |
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $50,207 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $27,015 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combin | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $19,220 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Ba | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $18,960 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pemb | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $18,700 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $16,846 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an | 2024 |
| 2024-12-31 | BIOTRONIK INC. | $16,500 | Debt forgiveness | Cash or cash equivalent | Intica Neo 7 HF-T DF-1 IS-1 ProMRI Device, Cardiology/Vascular Diseases | 2024 | |
| 2024-12-31 | Regeneron Pharmaceuticals, Inc. | $13,625 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | I-SPY 2 TRIAL (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $11,984 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $9,945 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,382 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,352 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,049 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind P | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,049 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,630 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in comb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,046 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,289 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,089 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $4,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Stryker Corporation | $3,966 | Long term medical supply or device loan | In-kind items and services | MV3 Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $3,697 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $3,110 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $3,095 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $2,500 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $2,193 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $1,658 | Research payment | In-kind items and services | A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Par | 2024 | |
| 2024-12-31 | ABBVIE INC. | $1,024 | Research payment | In-kind items and services | M23-647 ABBV-101 Ph1 RR NHL FIH | 2024 | |
| 2024-12-31 | Stryker Corporation | $882 | Long term medical supply or device loan | In-kind items and services | ARISE 1000 Ex Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $857 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | United Therapeutics Corporation | $770 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $645 | Long term medical supply or device loan | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Stryker Corporation | $645 | Long term medical supply or device loan | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $577 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $577 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $577 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $577 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | United Therapeutics Corporation | $484 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $469 | Long term medical supply or device loan | In-kind items and services | NA Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $394 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2024 |
| 2024-12-31 | Masimo Corporation | $285 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $285 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $285 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $285 | Long term medical supply or device loan | Cash or cash equivalent | SedLine Device, Devices | 2024 | |
| 2024-12-31 | United Therapeutics Corporation | $261 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | United Therapeutics Corporation | $76 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $59 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla | 2024 |
| 2024-12-30 | PFIZER INC. | $17,500 | Research payment | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | IDENTIFY SERUM BIOMARKERS AND S AUREUS RELATEDDRIVERS OF ATOPIC DERMATITIS SEVERITY | 2024 |
| 2024-12-28 | PFIZER INC. | $29,797 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-12-26 | Roche TCRC, Inc. | $13,868 | Research payment | Cash or cash equivalent | Phase II study in early stage Parkinson s Disease Patients | 2024 | |
| 2024-12-26 | Immedica Pharma US, Inc. | $11,172 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-26 | Immedica Pharma US, Inc. | $6,192 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-26 | Roche TCRC, Inc. | $1,972 | Research payment | Cash or cash equivalent | Phase II study in early stage Parkinson s Disease Patients | 2024 | |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $565 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $565 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-26 | Immedica Pharma US, Inc. | $554 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-26 | Regeneron Pharmaceuticals, Inc. | $211 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-25 | PFIZER INC. | $1,069 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,992 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,592 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,553 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,015 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $1,957 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | Baxter Healthcare | $680 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Renal - CRRT Device, Renal | 2024 | |
| 2024-12-23 | Kite Pharma, Inc. | $148,582 | Research payment | Cash or cash equivalent | Phenotypic and Functional Analysis of Kite CART Cells | 2024 | |
| 2024-12-23 | Gilead Sciences, Inc. | $101,000 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | Perspectives on Innovative HIV Treatment among Treatment Experienced Black Women Living with HIV Infection (in New York | 2024 |
| 2024-12-23 | Gilead Sciences, Inc. | $33,000 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | PrEP knowledge, preferences and initiation among Black and Hispanic/Latine transwomen in two US urban centers | 2024 |
| 2024-12-23 | Kite Pharma, Inc. | $15,400 | Research payment | Cash or cash equivalent | Phenotypic and Functional Analysis of Kite CART Cells | 2024 | |
| 2024-12-20 | Alcon Research LLC | $44,122 | Research payment | Cash or cash equivalent | Modeling and testing of different EDOF designs | 2024 | |
| 2024-12-20 | Shape Memory Medical Inc. | $2,573 | Research payment | Cash or cash equivalent | IMPEDE EMBOLIZATION PLUG Device, Vascular Embolization | AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion | 2024 |
| 2024-12-20 | Shape Memory Medical Inc. | $1,794 | Research payment | Cash or cash equivalent | IMPEDE EMBOLIZATION PLUG Device, Vascular Embolization | AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion | 2024 |
| 2024-12-20 | Shape Memory Medical Inc. | $1,423 | Research payment | Cash or cash equivalent | IMPEDE EMBOLIZATION PLUG Device, Vascular Embolization | AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | $530 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Randomized Double blind Placebo controlled Phase 3 Study of JNJ56021927 in Subjects with High risk Localized or Locall | 2024 |
| 2024-12-20 | W. L. Gore & Associates, Inc. | $332 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararena | 2024 |
| 2024-12-19 | AstraZeneca Pharmaceuticals LP | $4,412 | Research payment | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult an | 2024 |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,883 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,883 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,832 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,795 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,697 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,697 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,664 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,664 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,664 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,664 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,664 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,664 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,567 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,567 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,533 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,533 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $2,436 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,233 | Research payment | Cash or cash equivalent | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2024 | |
| 2024-12-19 | Regeneron Pharmaceuticals, Inc. | $1,826 | Research payment | Cash or cash equivalent | A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH C | 2024 | |
| 2024-12-19 | Incyte Corporation | $1,740 | Research payment | Cash or cash equivalent | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2024 | |
| 2024-12-18 | Novartis Pharmaceuticals Corporation | $55,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Kite Pharma, Inc. | $39,721 | Research payment | Cash or cash equivalent | Tecartus Drug, CELLT | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma | 2024 |
| 2024-12-17 | Eisai Inc. | $18,177 | Research payment | Cash or cash equivalent | Leqembi Drug, Neurology | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2024 |
| 2024-12-17 | Kite Pharma, Inc. | $4,728 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom | 2024 |
| 2024-12-17 | Kite Pharma, Inc. | $1,450 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL | 2024 |
| 2024-12-17 | Kite Pharma, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Kite Pharma, Inc. | $839 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | Collaborative: WAVE 1, A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patient | 2024 |
| 2024-12-17 | Kite Pharma, Inc. | $800 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera | 2024 |
| 2024-12-17 | Kite Pharma, Inc. | $793 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | Collaborative: A Phase 2 trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity. | 2024 |
| 2024-12-16 | Merck Sharp & Dohme LLC | $4,158 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2024 |
| 2024-12-13 | Abbott Laboratories | $239,741 | Research payment | Cash or cash equivalent | ENSITE PRECISION Device, ELECTROPHYSIOLOGY | Primary Preventive Vt Ablation in High Risk Patients Who Receive a Prophylatic ICD (PRIMARY PREVENT-VT) | 2024 |
| 2024-12-13 | Biogen, Inc. | $75,500 | Royalty or License | Cash or cash equivalent | SPINRAZA Biological, Neurology | 2024 | |
| 2024-12-13 | United Therapeutics Corporation | $6,840 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-13 | PFIZER INC. | $4,438 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2024 |
| 2024-12-13 | United Therapeutics Corporation | $2,863 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-13 | United Therapeutics Corporation | $2,160 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-13 | United Therapeutics Corporation | $2,128 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-13 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-13 | United Therapeutics Corporation | $780 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $565 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Regeneron Pharmaceuticals, Inc. | $536 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | 2024 |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $42 | Research payment | Cash or cash equivalent | SRP-9001-303 | 2024 | |
| 2024-12-12 | Immedica Pharma US, Inc. | $8,620 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-12 | Immedica Pharma US, Inc. | $3,000 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-12 | Immedica Pharma US, Inc. | $2,993 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-12 | Immedica Pharma US, Inc. | $2,689 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-12 | Immedica Pharma US, Inc. | $1,649 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-12 | Immedica Pharma US, Inc. | $1,391 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-12-11 | Incyte Corporation | $2,271 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2024 | |
| 2024-12-11 | United Therapeutics Corporation | $2,145 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-12-11 | Incyte Corporation | $1,586 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2024 | |
| 2024-12-11 | Incyte Corporation | $1,586 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2024 | |
| 2024-12-11 | Incyte Corporation | $1,546 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2024 | |
| 2024-12-11 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-11 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-10 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-06 | bioMerieux Inc | $4,408 | Research payment | Cash or cash equivalent | VITEK2 Device, Diagnostics | ETEST IRPA | 2024 |
| 2024-12-06 | bioMerieux Inc | $4,408 | Research payment | Cash or cash equivalent | VITEK2 Device, Diagnostics | ETEST IRPA | 2024 |
| 2024-12-06 | Medical Device Business Services, Inc. | $3,750 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-06 | Stryker Corporation | $2,000 | Research payment | Cash or cash equivalent | AUGMENT INJECTABLE PAS | 2024 | |
| 2024-12-06 | Medtronic, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | ABBVIE INC. | $334 | Research payment | Cash or cash equivalent | A Trial of the Efficacy and Safety of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures | 2024 | |
| 2024-12-04 | Merck Sharp & Dohme LLC | $19,223 | Research payment | Cash or cash equivalent | Drug, INFECTIOUS DISEASE | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an | 2024 |
| 2024-12-04 | PFIZER INC. | $8,464 | Research payment | Cash or cash equivalent | PROTONIX Drug, GASTROINTESTINAL | AN EXPLORATORY MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF CLINICAL OUTCOMES TOLERABILITY AND SAFETY OF 2 DOSES OF ORAL | 2024 |
| 2024-12-04 | PFIZER INC. | $7,168 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2024 |
| 2024-12-04 | Merck Sharp & Dohme LLC | $1,852 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2024 |
| 2024-12-03 | Janssen Research & Development, LLC | $1,119 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Randomized Double blind Placebo controlled Phase 3 Study of JNJ56021927 in Subjects with High risk Localized or Locall | 2024 |
| 2024-12-02 | PFIZER INC. | $76,733 | Research payment | Cash or cash equivalent | THE MICROBIOLOGY AND CLINICAL OUTCOMES OF MODERATE TO SEVERE ACUTE RESPIRATORY INFECTIONS IN HOSPITALIZED ADULTS AFTER T | 2024 | |
| 2024-12-02 | PFIZER INC. | $42,298 | Research payment | Cash or cash equivalent | THE MICROBIOLOGY AND CLINICAL OUTCOMES OF MODERATE TO SEVERE ACUTE RESPIRATORY INFECTIONS IN HOSPITALIZED ADULTS AFTER T | 2024 | |
| 2024-12-02 | PFIZER INC. | $38,629 | Research payment | Cash or cash equivalent | THE MICROBIOLOGY AND CLINICAL OUTCOMES OF MODERATE TO SEVERE ACUTE RESPIRATORY INFECTIONS IN HOSPITALIZED ADULTS AFTER T | 2024 | |
| 2024-12-02 | ABBVIE INC. | $31,511 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Change in Disease Activity and How Oral ABBV-101 Moves Through the Body in Adult Partic | 2024 | |
| 2024-12-02 | Incyte Corporation | $236 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2024 | |
| 2024-12-01 | Regeneron Pharmaceuticals, Inc. | $149 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-11-27 | AstraZeneca UK Limited | $70,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-27 | Sarepta Therapeutics, Inc. | $3,564 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-11-27 | Sarepta Therapeutics, Inc. | $3,088 | Research payment | Cash or cash equivalent | SRP-9001-303 | 2024 | |
| 2024-11-27 | Zimmer Biomet Holdings, Inc. | $1,994 | Research payment | Cash or cash equivalent | Comprehensive Shoulder System Device, Extremities | MDR Comprehensive Primary Micro Stem Titanium Versa-Dial Humeral Head | 2024 |
| 2024-11-27 | Sarepta Therapeutics, Inc. | $1,300 | Research payment | Cash or cash equivalent | SRP-9001-303 | 2024 | |
| 2024-11-27 | Sarepta Therapeutics, Inc. | $1,300 | Research payment | Cash or cash equivalent | SRP-9001-303 | 2024 | |
| 2024-11-26 | Sarepta Therapeutics, Inc. | $44,000 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-11-26 | United Therapeutics Corporation | $7,650 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $6,840 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $4,456 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $1,900 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-11-26 | Immedica Pharma US, Inc. | $1,691 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2024 | |
| 2024-11-25 | Genentech, Inc. | $9,833 | Research payment | Cash or cash equivalent | Phase II study of RO7269162 in participants with prodromal to mild AD | 2024 | |
| 2024-11-25 | Janssen Research & Development, LLC | $6,756 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | A Phase 2a Multi Center Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered | 2024 |
| 2024-11-25 | Kite Pharma, Inc. | $4,428 | Research payment | Cash or cash equivalent | A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with R | 2024 | |
| 2024-11-25 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | CARPEDIEM Device, Hematology | CARPEDIEM Study | 2024 |
| 2024-11-25 | Kite Pharma, Inc. | $180 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL | 2024 |
| 2024-11-22 | Sarepta Therapeutics, Inc. | $134,743 | Research payment | Cash or cash equivalent | Amondys 45 Drug, Genetic Disease | 4045-301 | 2024 |
| 2024-11-22 | United Therapeutics Corporation | $14,434 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2024 | |
| 2024-11-22 | Stryker Corporation | $2,000 | Research payment | Cash or cash equivalent | AUGMENT INJECTABLE PAS | 2024 | |
| 2024-11-22 | HARMONY BIOSCIENCES LLC | $1,594 | Research payment | Cash or cash equivalent | WAKIX Drug, Narcolepsy | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myoto | 2024 |
| 2024-11-21 | Janssen Research & Development, LLC | $45,594 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su | 2024 | |
| 2024-11-21 | Tanabe Pharma America, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-19 | Kite Pharma, Inc. | $44,170 | Research payment | Cash or cash equivalent | Tecartus Drug, CELLT | A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma | 2024 |
| 2024-11-19 | Kite Pharma, Inc. | $10,829 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom | 2024 |
| 2024-11-19 | Kite Pharma, Inc. | $6,975 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera | 2024 |
| 2024-11-19 | HARMONY BIOSCIENCES LLC | $5,084 | Research payment | Cash or cash equivalent | WAKIX Drug, Narcolepsy | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myoto | 2024 |
| 2024-11-19 | Kite Pharma, Inc. | $3,887 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | Collaborative: WAVE 1, A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patient | 2024 |
| 2024-11-19 | United Therapeutics Corporation | $2,419 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-11-19 | United Therapeutics Corporation | $2,298 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
The latest 200 records of 1,509.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rochester, NY, county Monroe County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Rochester, NY | County Monroe County, NY | State New York |
|---|---|---|---|
| Population B01003 | 208,772 | 753,753 | 19,852,366 |
| Population, 2020 census P1 | 211,328 | 759,443 | 20,201,249 |
| Median age B01002 | 33.7 | 39.6 | 39.8 |
| Under 18 B01001 | 20.9% | 20.3% | 20.5% |
| 65 and over B01001 | 13.1% | 18.8% | 17.9% |
| Households B11001 | 93,261 | 318,428 | 7,722,646 |
| Foreign born B05002 | 8.2% | 7.9% | 22.8% |
| Median household income B19013 | $47,213 | $76,382 | $85,974 |
| Median family income B19113 | $57,673 | $102,166 | $106,873 |
| Per capita income B19301 | $31,314 | $44,107 | $50,712 |
| Poverty rate B17001 | 27.8% | 13.6% | 14.0% |
| Unemployment rate B23025 | 7.9% | 4.9% | 6.4% |
| Civilian labor force B23025 | 105,136 | 391,197 | 10,171,766 |
| Mean commute (minutes) B08013 | 19.3 | 19.9 | 32.6 |
| Bachelor's degree or higher B15003 | 30.0% | 41.5% | 40.2% |
| Housing units B25001 | 104,479 | 339,430 | 8,585,241 |
| Owner-occupied B25003 | 38.1% | 63.7% | 54.3% |
| Renters B25003 | 61.9% | 36.3% | 45.7% |
| Median home value B25077 | $139,600 | $213,700 | $423,800 |
| Median gross rent B25064 | $1,081 | $1,173 | $1,621 |
| White, not Hispanic B03002 | 36.4% | 67.7% | 52.8% |
| Black B03002 | 34.7% | 13.5% | 13.4% |
| Hispanic or Latino B03002 | 19.6% | 9.9% | 19.8% |
| Asian B03002 | 3.2% | 3.8% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rochester, NY.
Comments